Evaluation of benzyltetrahydroisoquinolines as ligands for neuronal nicotinic acetylcholine receptors
Artículo
Open/ Download
Publication date
2005-06-27Metadata
Show full item record
Cómo citar
Exley, Richard
Cómo citar
Evaluation of benzyltetrahydroisoquinolines as ligands for neuronal nicotinic acetylcholine receptors
Author
Abstract
1 Effects of derivatives of coclaurine (C), which mimic the ‘eastern’ or the nonquaternary halves of
the alkaloids tetrandrine or d-tubocurarine, respectively, both of which are inhibitors of nicotinic
acetylcholine receptors (nACh), were examined on recombinant, human a7, a4b2 and a4b4 nACh
receptors expressed in Xenopus oocytes and clonal cell lines using two-electrode voltage clamping and
radioligand binding techniques.
2 In this limited series, Cs have higher affinity and are most potent at a4 subunit-containing-nACh
receptors and least potent at homomeric a7 receptors, and this trend is very marked for the
N-unsubstituted C and its O,O0-bisbenzyl derivative.
3 7-O-Benzyl-N-methylcoclaurine (BBCM) and its 12-O-methyl derivative showed the highest
affinities and potencies at all three receptor subtypes, and this suggests that lipophilicity at C7 and/or
C12 increases potency.
4 Laudanosine and armepavine (A) were noncompetitive and voltage-dependent inhibitors of a7,
a4b2 or a4b4 receptors, but the bulkier C7-benzylated 7BNMC (7-O-benzyl-N-methylcoclaurine) and
7B12MNMC (7-O-benzyl-N,12-O-dimethyl coclaurine) were voltage-independent, noncompetitive
inhibitors of nACh receptors. Voltage-dependence was also lost on going from A to its N-ethyl
analogue.
5 These studies suggest that C derivatives may be useful tools for studies characterising the
antagonist and ion channel sites on human a7, a4b2 or a4b4 nACh receptors and for revealing
structure–function relationships for nACh receptor antagonists.
Patrocinador
This work was funded in part by a Wellcome Trust CRIG and ICM
Grant No. P99-031-F. B.K.C. acknowledges a generous gift of
equipment from the Alexander von Humboldt Foundation (Germany).
R. Exley was funded by a BBSRC-Eli Lilly Case PhD studentship.
Funding from National Institutes of Health grants NS40417 and
DA015389, from Arizona Disease Control Research Commission
grants 9730and 9615, and by endowment and/or capitalization funds
from the Men’s and Women’s Boards of the Barrow Neurological
Foundation also is acknowledged (R.J.L.).
Quote Item
British Journal of Pharmacology, Vol. 146, p. 15–24, 2005.
Collections